Market revenue in 2024 | USD 459.8 million |
Market revenue in 2030 | USD 484.1 million |
Growth rate | 0.4% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 60.48% in 2024. Horizon Databook has segmented the Canada anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Canada’s anti-VEGF therapeutics market is anticipated to witness significant growth, owing to increasing disease burden, product launches, and R&D activities for testing potential treatments of AMD. According to FIGHTING BLINDNESS CANADA, around 1.4 million Canadians are affected by AMD.
In October 2020, Novartis AG announced the introduction of Beovu (brolucizumab injection) in Canada for the treatment of wet AMD. This VEGF inhibitor enables patients to start on 3-month dosing intervals after the loading phase. This novel treatment received a positive recommendation for reimbursement under public health plans.
Key players are focusing on the adoption of marketing strategies, such as research collaborations, licensing agreements, and product launches, for sustaining themselves in the market. For instance, in January 2020, Coherus BioSciences, Inc. entered into a licensing agreement with Innovent Biologics, Inc. for the commercialization of IBI305, a biosimilar candidate of Avastin (bevacizumab) in Canada.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Canada anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account